 | Up a level |
Kamdar, Manali; Solomon, Scott R; Arnason, Jon; Johnston, Patrick B; Glass, Bertram; Bachanova, Veronika; Ibrahimi, Sami; Mielke, Stephan; Mutsaers, Pim; Hernandez-Ilizaliturri, Francisco; Izutsu, Koji; Morschhauser, Franck; Lunning, Matthew; Maloney, David G; Crotta, Alessandro; Montheard, Sandrine; Previtali, Alessandro; Stepan, Lara; Ogasawara, Ken; Mack, Timothy; ... (2022). Lisocabtagene maraleucel versus standard of care with salvage chemotherapy followed by autologous stem cell transplantation as second-line treatment in patients with relapsed or refractory large B-cell lymphoma (TRANSFORM): results from an interim analysis of an open-label, randomised, phase 3 trial. Lancet, 399(10343), pp. 2294-2308. Elsevier 10.1016/S0140-6736(22)00662-6
Castillo, Jorge J; Bower, Mark; Brühlmann, Jérémy; Novak, Urban; Furrer, Hansjakob; Tanaka, Paula Y; Besson, Caroline; Montoto, Silvia; Cwynarski, Kate; Abramson, Jeremy S; Dalia, Samir; Bibas, Michele; Connors, Joseph M; Furman, Michael; Nguyen, Minh-Ly; Cooley, Timothy P; Beltran, Brady E; Collins, Jaime A; Vose, Julie M; Xicoy, Blanca; ... (2014). Prognostic factors for advanced-stage human immunodeficiency virus-associated classical Hodgkin lymphoma treated with doxorubicin, bleomycin, vinblastine, and dacarbazine plus combined antiretroviral therapy: A multi-institutional retrospective study. Cancer research, 121(3), pp. 423-431. American Association for Cancer Research AACR 10.1002/cncr.29066
